ARTICLE SUMMARY:
The success of transcatheter aortic valve implants (TAVI/TAVR), estimated to be a $2 billion global market in 2015, has sparked considerable interest among entrepreneurs and investors in applying the same principle – shifting from open surgery to percutaneous procedures – to the mitral valve (MV) space.
The success of transcatheter aortic valve implants (TAVI/TAVR), estimated to be a $2 billion global market in 2015, has sparked considerable interest among entrepreneurs and investors in applying the same principle – shifting from open surgery to percutaneous procedures – to the mitral valve (MV) space.
